TGF-beta RIII Antibody [Unconjugated]

TGF‑ beta RIII was detected in immersion fixed paraffin-embedded sections of human placenta tissue using Goat Anti-Human TGF‑ beta RIII Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-242-PB) at 1 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell surface on syncytiotrophoblast cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

PC‑3 human prostate cancer cell line was stained with Goat Anti-Human TGF‑ beta RIII Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF‑242‑PB, filled histogram) or isotype control antibody (Catalog # AB-108-C, open histogram), followed by Fluorescein-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0109).

MCF-7 human breast adenocarcinoma cell line was stained with Goat Anti-Human TGF-beta RIII Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-242-PB, filled histogram) or control antibody (AB-108-C, open histogram), followed by PE-conjugated Anti-Goat IgG Secondary Antibody (F0107).

• Reactivity: Hu
• Applications: WB, Flow, IHC, CyTOF-ready
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

TGF-beta RIII Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TGF‑ beta RIII
  Gly21-Asp781
  Accession # AAA67061
• Specificity: Detects human TGF-beta RIII in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant mouse (rm) TGF-beta RIII is observed, and less than 1% cross-reactivity with recombinant human (rh) TGF-beta RI, rhTGF-beta RII, rhTGF-beta RIIB, and rmTGF-beta RI is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: TGFBR3
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.25 ug/10^6 cells
  • Immunohistochemistry 1-15 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TGF-beta RIII Antibody [Unconjugated]

• betaglycan proteoglycan
• Betaglycan
• BGCAN
• TBRIII
• TGF-beta receptor type 3
• TGF-beta receptor type III
• TGF-beta RIII
• TGFbetaRIII
• TGFBR3
• TGF-bRIII
• TGFR-3
• Transforming growth factor beta receptor III
• transforming growth factor beta receptor type 3
• transforming growth factor, beta receptor III (betaglycan, 300kDa)
• transforming growth factor, beta receptor III

Background

Most cell types express three sizes of receptors for TGF-beta . These are designated Type I (53 kDa), Type II (70-85 kDa), and Type III (250-350 kDa). The Type I receptor is a membrane-bound serine/threonine kinase that apparently requires the presence of the Type II receptor to bind TGF-beta . The Type II receptor is also a membrane-bound serine/threonine kinase that binds TGF-beta 1 and TGF-beta 3 with high affinity and TGF-beta 2 with a much lower affinity. The Type I and Type II receptors together form a heterodimeric signaling complex that is essential for the transduction of the anti-proliferative signals of TGF-beta .

The Type III receptor is a transmembrane proteoglycan with a large extracellular domain and a 43 amino acid residue cytoplasmic domain. The cytoplasmic domain of the Type III receptor lacks an obvious signaling motif and the receptor may not be involved directly in signal transduction. The Type III receptor binds TGF-beta 2 with the highest affinity. Other TGF-beta isoforms also bind the Type III receptor, but with lower affinities. Cellular responsiveness to TGF-beta 2 appears to be dependent on the presence of the Type III receptor which can interact with the signaling receptor complex. In addition to the transmembrane Type III receptor, a soluble form of the receptor is secreted by some cell types. The physiological role of this soluble receptor remains to be determined. The recombinant TGF-beta soluble receptor Type III binds the TGF-beta isoforms differentially in solution and exhibits TGF-beta antagonistic activities in vitro.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TGF-beta RIII Antibody (AF-242-PB)(9)

Publications using AF-242-PB

• F Facciotti, P Larghi, R Bosotti, C Vasco, N Gagliani, C Cordiglier, S Mazzara, V Ranzani, E Rottoli, S Curti, A Penatti, B Karnani, Y Kobayashi, M Crosti, M Bombaci, JP van Hambur, G Rossetti, R Gualtierot, M Gerosa, S Gatti, S Torretta, L Pignataro, SW Tas, S Abrignani, M Pagani, F Grassi, PL Meroni, RA Flavell, J Geginat Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6+B helper T cells in systemic lupus erythematosus Proc. Natl. Acad. Sci. U.S.A., 2020;117(13):7305-7316. 2020 [PMID: 32184325] (Flow Cytometry, Human)
• Karthikeyan Mythreye Altering the Proteoglycan State of Transforming Growth Factor ? Type III Receptor (T?RIII)/Betaglycan Modulates Canonical Wnt/?-Catenin Signaling J. Biol. Chem., 2016;291(49):25716-25728. 2016 [PMID: 27784788] (Immunoprecipitation)
• Drasin D, Guarnieri A, Neelakantan D, Kim J, Cabrera J, Wang C, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan A, Ford H TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Res, 2015;75(9):1908-21. 2015 [PMID: 25716682] (Flow Cytometry, Human)
• Wang F, Zhou Y, Fu B, Wu Y, Zhang R, Sun R, Tian Z, Wei H Molecular signatures and transcriptional regulatory networks of human immature decidual NK and mature peripheral NK cells. Eur J Immunol, 2014;44(9):2771-84. 2014 [PMID: 24838931] (Flow Cytometry, Human)
• Murphy MO, Ghosh J, Fulford P, Khwaja N, Halka AT, Carter A, Turner NJ, Walker MG Expression of growth factors and growth factor receptor in non-healing and healing ischaemic ulceration. Eur J Vasc Endovasc Surg, 2006;31(5):516-22. 2006 [PMID: 16427789] (IHC, Human)
• Florio P, Ciarmela P, Reis FM, Toti P, Galleri L, Santopietro R, Tiso E, Tosi P, Petraglia F Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma. Eur. J. Endocrinol., 2005;152(2):277-84. 2005 [PMID: 15745937] (IHC-P, Human)
• Rosado E, 2019, Schwartz Z, Sylvia VL, Dean DD, Boyan BD Transforming growth factor-beta1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways. 91, 2002;1590(1):1-15. 2002 [PMID: 12063164] (Neutralization, Rat)
• Bandyopadhyay A, 2019, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F, Sun LZ Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. 101205, 2002;21(22):3541-51. 2002 [PMID: 12032856] (ELISA Development, Human)
• Song QH, Klepeis VE, Trinkaus-Randall V TGF-beta1 regulates TGF-beta1 and FGF-2 mRNA expression during fibroblast wound healing. MP, Mol. Pathol., 2002;55(3):164-76. 2002 [PMID: 12032227] (IHC, Rabbit)

Bioinformatics

• Gene Symbol: TGFBR3
• Uniprot:
  • AAA67061()